Rather than binding to a single metabolic receptor, this research peptide is engineered to interact with three distinct receptor targets involved in glucose and lipid metabolism: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor
Barra minn hekk, GLP-1 jista 'wkoll jaffettwa l-interazzjoni bejn mikrobijota orali u l-ospitanti billi jirregola l-funzjoni immuni tal-mukua orali
The 1200mg dose provides therapeutic levels that cannot be achieved through oral supplementation due to poor absorption
Bioresource Technology, 316: 123968 Daims H, Lebedeva E V, Pjevac P, Han P, Herbold C, Albertsen M, Jehmlich N, Palatinszky M, Vierheilig J, Bulaev A, et al